Literature DB >> 29506920

ECFS best practice guidelines: the 2018 revision.

Carlo Castellani1, Alistair J A Duff2, Scott C Bell3, Harry G M Heijerman4, Anne Munck5, Felix Ratjen6, Isabelle Sermet-Gaudelus7, Kevin W Southern8, Jurg Barben9, Patrick A Flume10, Pavla Hodková11, Nataliya Kashirskaya12, Maya N Kirszenbaum13, Sue Madge14, Helen Oxley15, Barry Plant16, Sarah Jane Schwarzenberg17, Alan R Smyth18, Giovanni Taccetti19, Thomas O F Wagner20, Susan P Wolfe21, Pavel Drevinek22.   

Abstract

Developments in managing CF continue to drive dramatic improvements in survival. As newborn screening rolls-out across Europe, CF centres are increasingly caring for cohorts of patients who have minimal lung disease on diagnosis. With the introduction of mutation-specific therapies and the prospect of truly personalised medicine, patients have the potential to enjoy good quality of life in adulthood with ever-increasing life expectancy. The landmark Standards of Care published in 2005 set out what high quality CF care is and how it can be delivered throughout Europe. This underwent a fundamental re-write in 2014, resulting in three documents; center framework, quality management and best practice guidelines. This document is a revision of the latter, updating standards for best practice in key aspects of CF care, in the context of a fast-moving and dynamic field. In continuing to give a broad overview of the standards expected for newborn screening, diagnosis, preventative treatment of lung disease, nutrition, complications, transplant/end of life care and psychological support, this consensus on best practice is expected to prove useful to clinical teams both in countries where CF care is developing and those with established CF centres. The document is an ECFS product and endorsed by the CF Network in ERN LUNG and CF Europe.
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Best practice; Consensus; Cystic fibrosis; Guidelines; Multidisciplinary management; Standards of care

Mesh:

Year:  2018        PMID: 29506920     DOI: 10.1016/j.jcf.2018.02.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  120 in total

1.  Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Authors:  Miquel B Ekkelenkamp; Rafael Cantón; María Díez-Aguilar; Michael M Tunney; Deirdre F Gilpin; Francesca Bernardini; Glenn E Dale; J Stuart Elborn; Jumamurat R Bayjanov; Ad Fluit
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

3.  Respiratory physical therapy techniques recommended for patients with cystic fibrosis treated in specialized centers.

Authors:  Márcio Vinícius Fagundes Donadio; Natália Evangelista Campos; Fernanda Maria Vendrusculo; Augusta Machado Stofella; Ana Carolina da Silva Almeida; Bruna Ziegler; Camila Isabel Santos Schivinski; Cíntia Helena Santuzzi; Edilene do Socorro Nascimento Falcão Sarges; Fernanda Mayrink Gonçalves; Maria Ângela Gonçalves de Oliveira Ribeiro; Nelbe Nesi Santana; Sarah Bezerra de Paiva; Vanessa Cristina Waetge Pires de Godoy; Evanirso da Silva Aquino
Journal:  Braz J Phys Ther       Date:  2019-11-29       Impact factor: 3.377

4.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

5.  Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis.

Authors:  Tasma Harindhanavudhi; Qi Wang; Jordan Dunitz; Antoinette Moran; Amir Moheet
Journal:  J Cyst Fibros       Date:  2019-11-11       Impact factor: 5.482

Review 6.  The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease.

Authors:  Theodore G Liou
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

Review 7.  [Evidence-based treatment of cystic fibrosis].

Authors:  F C Ringshausen; T Hellmuth; A-M Dittrich
Journal:  Internist (Berl)       Date:  2020-12       Impact factor: 0.743

8.  National Newborn Screening for cystic fibrosis in the Republic of Ireland: genetic data from the first 6.5 years.

Authors:  Erina Sasaki; Marija Kostocenko; Niamh Lang; Tara Clark; Melissa Rogers; Rebecca Muldowney; Olivia Walsh; Loretta O'Grady; Gillian Edge; Alana Ward; Barry Linnane; Ingrid Borovickova; David E Barton; Sally Ann Lynch
Journal:  Eur J Hum Genet       Date:  2020-06-01       Impact factor: 4.246

9.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Authors:  Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy
Journal:  Lancet       Date:  2019-10-31       Impact factor: 79.321

Review 10.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.